Sun Pharma to buy GSK’s opiates biz in Oz

By: |
Updated: March 23, 2015 10:34 AM

To buy GSK’s opiates business in Australia

To buy GSK’s opiates business in Australia

GlaxoSmithKline (GSK) and Sun Pharmaceutical Industries announced that their respective, wholly-owned subsidiaries have reached an agreement related to GSK’s opiates business in Australia.

The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) as well as its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma.

The product portfolio consists of poppy-derived opiate raw materials that are primarily used in the manufacture of analgesics for the treatment of moderate to severe pain.

All employees from both sites will also be offered employment by Sun with the opiates business. Both Sun Pharma and GSK believe that the future of the opiates business will be secured as part of Sun Pharma, a company with a global footprint.

The transaction will allow GSK to simplify its operations in Australia and allow it to focus on delivering its innovative product portfolio that will be central to the company’s growth strategy in this country.

Steve Morris, General Manager, GSK Opiates said, “The opiates business has been an important part of our Australian business for many years, but as our portfolio transitions, we believe now is the right time to hand this business over to someone else.”

Iftach Seri, Executive Vice President of API business, Sun Pharma said, “The global opiates market holds good potential and the addition of GSK’s opiates business will strengthen our positioning further. The acquisition is a part of our strategy towards building our portfolio of opiates and accessing strong capabilities in this segment.”

EP News BureauMumbai

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Samyukta Kisan Morcha to meet tomorrow to decide on ending protest after consensus on fresh proposal by government
2Centre blocked around 20,000 URLs between 2014-2020, half of them in 2020 alone, MeitY tells Parliament
3Explained: What is the Assisted Reproductive Technology (Regulation) Bill 2021 passed by Parliament?